FUJIY - FUJIFILM Holdings Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
43.79
+1.07 (+2.50%)
At close: 3:45PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close42.72
Open45.28
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.03 - 45.28
52 Week Range36.60 - 58.00
Volume28,342
Avg. Volume40,744
Market Cap17.766B
Beta (5Y Monthly)0.35
PE Ratio (TTM)15.45
EPS (TTM)2.84
Earnings DateN/A
Forward Dividend & Yield0.89 (2.07%)
Ex-Dividend DateMar 27, 2020
1y Target Est40.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet
    Reuters

    Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet

    Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India. Glenmark last month received Indian regulatory approval to make and sell anti-flu drug favipiravir, which is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp.

  • Reuters

    Fujifilm's Avigan inconclusive in COVID-19 patients in Japan trial

    A clinical trial of Fujifilm Holdings Corp's Avigan drug yielded inconclusive results as a treatment of COVID-19, Japanese researchers said on Friday. Although patients given the drug early in the trial showed more improvement than those who got delayed doses, the results did not reach statistical significance, Fujita Health University researcher Yohei Doi said. The results, announced at a news conference on Friday, followed the completion of a clinical trial conducted between March and May on 89 patients across Japan.

  • Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug
    Zacks

    Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

    Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

  • Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment
    Reuters

    Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

    Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia. The deal comes as global drug makers rush to get factories ready for large-scale production of potential treatment and vaccines for COVID-19, the respiratory disease caused by the coronavirus, and move ahead with clinical trials. Fujifilm is conducting a clinical study on Avigan to treat COVID-19 patients in Japan and the United States and has been seeking to increase the drug's production by partnering with domestic and overseas companies.

  • New Strong Sell Stocks for June 16th
    Zacks

    New Strong Sell Stocks for June 16th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Reuters

    Japan's Fujifilm to spend $928 million to double capacity of Danish drug facility

    Fujifilm Holdings Corp <4901.T> will spend $928 million to double capacity at a drug manufacturing facility in Denmark, which it has pledged to use in producing COVID-19 treatments, as the Japanese company steps up its pivot towards healthcare. The investment in Fujifilm Diosynth Biotechnologies will expand production lines for bulk drug substances and cultivate cells for producing viral vaccines, Fujifilm announced on Tuesday. It bought the facility in Hillerod, Denmark, in August from Biogen Inc <BIIB.O> for about $890 million.

  • New Strong Sell Stocks for June 8th
    Zacks

    New Strong Sell Stocks for June 8th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Fujifilm says COVID-19 drug research may drag on into July
    Reuters

    Fujifilm says COVID-19 drug research may drag on into July

    Fujifilm Holdings Corp's <4901.T> research on Avigan as a potential treatment for COVID-19 may drag on until July, the company said on Sunday, a further setback for the Japanese firm's effort to prove the drug's effectiveness against the virus. "There is a possibility that clinical trials will continue in July," a Fujifilm spokesman said, responding to a Nikkei report that any approval will be delayed until July or later, due to a lack of patients for trials. After the government of Prime Minister Shinzo Abe gave up on getting approval for the drug by the end of May, the aim was to complete clinical trials this month.

  • Reuters

    CORRECTED-Fujifilm says COVID-19 drug research may drag on into July

    Fujifilm Holdings Corp's research on Avigan as a potential treatment for COVID-19 may drag on until July, the company said on Sunday, a further setback for the Japanese firm's effort to prove the drug's effectiveness against the virus. "There is a possibility that clinical trials will continue in July," a Fujifilm spokesman said, responding to a Nikkei report that any approval will be delayed until July or later, due to a lack of patients for trials. After the government of Prime Minister Shinzo Abe gave up on getting approval for the drug by the end of May, the aim was to complete clinical trials this month.

  • Fujifilm COVID-19 drug research spills into June, dashing hopes of quick approval
    Reuters

    Fujifilm COVID-19 drug research spills into June, dashing hopes of quick approval

    Fujifilm Holdings Corp will continue research on Avigan into June, Japan's government said on Tuesday, effectively dashing hopes by Prime Minister Shinzo Abe that the drug would be approved as a COVID-19 treatment this month. Abe had said he hoped the drug would be approved in May if its efficacy and safety could be confirmed. "The company will continue research into next month or so, and if an application for approval is received from the company, it will be promptly reviewed," Chief Cabinet Secretary Yoshihide Suga said at a regular briefing when asked about Avigan.

  • Here are the ‘hot dogs’ that hedge funds have used to outperform this year
    MarketWatch

    Here are the ‘hot dogs’ that hedge funds have used to outperform this year

    Hedge funds have relied on technology, internet, media and telecom companies and increasingly more health care companies to drive performance.

  • MarketWatch

    Fujifilm shares fall amid doubts about Covid-19 treatment Avigan

    Shares of Fujifilm fell 2.7% in Tokyo on Wednesday amid doubts over a treatment for coronavirus infections. Interim results on clinical tests of the drug Avigan -- developed by the company's Toyama Chemical unit -- showed no clear signs of halting the virus's growth in patients, Kyodo News reported Tuesday, citing sources. A spokesperson from Fujiflm could not immediately be reached for comment. Japan's government has been hoping that the drug, approved in 2014 for use as an emergency flu treatment, would get the OK for use by the end of the month to treat the virus.

  • Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials
    Reuters

    Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials

    Shares of Fujifilm Holdings Corp fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials. The data reported to Japan's health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether the drug can be approved by the end of this month as sought by Japan's government, the report said, citing unidentified sources. The government has not changed its plans to promptly seek approval for Avigan if its efficacy and safety can be confirmed, Chief Cabinet Secretary Yoshihide Suga said on Wednesday.

  • CORRECTED-A tale of two Japanese drugs in tests to fight COVID-19
    Reuters

    CORRECTED-A tale of two Japanese drugs in tests to fight COVID-19

    In the global hunt for coronavirus treatments, a Japanese antiviral medicine known as Avigan has won plaudits from Prime Minister Shinzo Abe and $128 million in government funding. Camostat, a 35-year old pancreatitis drug made by Osaka-based Ono Pharmaceutical Co, has captured the interest of scientists in Japan and overseas with little fanfare or state assistance. The two compounds are among dozens undergoing testing around the globe and illustrate how the race to develop treatments and vaccines is still wide open despite politicians such as Abe and U.S. President Donald Trump promoting the potential benefits of certain drugs.

  • Should You Buy FUJIFILM (FUJIY) Ahead of Earnings?
    Zacks

    Should You Buy FUJIFILM (FUJIY) Ahead of Earnings?

    FUJIFILM (FUJIY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

  • TheStreet.com

    Indian Generic Maker Glenmark Seeks to Make Japanese Covid-19 Drug

    India's drugmakers aim to manufacture generic versions of any coronavirus 'cure', even before the full findings as to how effective they are.

  • Moody's

    Yestar Healthcare Holdings Company Limited -- Moody's downgrades Yestar's ratings to B1; outlook remains negative

    Moody's Investors Service has downgraded the corporate family rating (CFR) and senior unsecured rating of Yestar Healthcare Holdings Company Limited to B1 from Ba3. "The downgrade and negative outlook reflect our expectation that Yestar's liquidity and operating performance will weaken over the next 12-18 months, leaving it vulnerable to operating environment fluctuations amid its higher funding needs, and positioning it in the B rating category," says Gerwin Ho, a Moody's Vice President and Senior Credit Officer.

  • Coronavirus drug hopefuls are cheap to make but may be in short supply
    Reuters

    Coronavirus drug hopefuls are cheap to make but may be in short supply

    Drugs being re-purposed in hopes they will help against COVID-19 cost little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert said. "Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively," Andrew Hill, a University of Liverpool research fellow, told Reuters. In a study released Friday in the Journal of Virus Eradication, Hill and five other researchers, including Howard University chemist Joseph Fortunak, examined the cost of manufacturing medicines in recent or ongoing COVID-19 trials.

  • Fujifilm says new coronavirus test can produce results in two hours
    Reuters

    Fujifilm says new coronavirus test can produce results in two hours

    Fujifilm Holdings Corp <4901.T> said it has developed a new, faster test for the novel coronavirus that causes the COVID-19 disease, reducing the time of results delivery to about two hours. The test was developed by subsidiary Fujifilm Wako Pure Chemical Corp and will be released on April 15, the company said on Friday. The SARS-CoV-2 RT-qPCR detection kit will be able to test for the virus faster than existing polymerase chain reaction (PCR) tests, which take four to six hours, the company said.

  • TheStreet.com

    3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments

    Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.

  • TheStreet.com

    Mild Good News as Japanese Flu Drug Shows Promise in Mild Covid-19 Cases

    Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.

  • Fujifilm Shares Skyrocket As China Says Its Flu Medicine Works For Coronavirus
    Benzinga

    Fujifilm Shares Skyrocket As China Says Its Flu Medicine Works For Coronavirus

    The shares of FUJIFILM Holdings Corporation (OTC: FUJIY) hit their daily permissible high limit on Wednesday's open in Tokyo.What Happened The massive jump in an otherwise bearish market came as China suggested that an influenza medicine developed by subsidiary FUJIFILM Toyama Chemical Co. Ltd. is also effective against the novel coronavirus (COVID-19)."It has a high degree of safety and is clearly effective in treatment," the director of the Chinese science ministry's China National Center for Biotechnology Development, Zhang Xinmin said, according to the Nikkei Asian Review.Japan has been administering the medicine to coronavirus patients since February, The Nikkei noted. Toyama Chemical developed the drug, sold under the brand name Avigan, in 2014 as a medicine to combat the flu.Why It Matters Zhejiang Hisun Pharmaceutical Co Ltd, which signed a patent-licensing agreement with Fujifilm for the generic drug Favipiravir, received approval from Chinese authorities in February to conduct clinical trials for effectiveness against COVID-19, as reported by Reuters at the time.About 200 patients at hospitals in Chinese cities of Wuhan and Shenzhen are said to have participated in the trials, according to the Nikkei.The spread of the coronavirus has slowed down drastically in China to double-digits, with a total of 81, 086 cases, according to data from Johns Hopkins University. More than 3,200 people have died from COVID-19 in China, and another 4,713 have died outside the country.Price Action Fujifilm's shares traded 15.43% higher at $48.94 in Tokyo at press time on Wednesday. The shares closed 19.51% higher at $47.90 in the otc market on Tuesday.See more from Benzinga * US And Canada To Close Border For All Non-Essential Travel:Report * Toyota Partners With China's Momenta To Commercialize HD Maps For Self-Driving Vehicles * Tesla Shares Drop As Alameda County Says Fremont Factory 'Not An Essential Business'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Fujifilm shares jump 15% on China coronavirus drug trial boost
    Reuters

    Fujifilm shares jump 15% on China coronavirus drug trial boost

    TOKYO/BEIJING (Reuters) - Shares in Japan's Fujifilm Holdings Corp surged 15% on Wednesday after a Chinese official said an active ingredient of the company's Avigan anti-flu drug appeared to help coronavirus patients recover. Avigan, also known as Favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014.

  • FUJIFILM (FUJIY) to Report Q3 Earnings: What's in the Cards?
    Zacks

    FUJIFILM (FUJIY) to Report Q3 Earnings: What's in the Cards?

    FUJIFILM's (FUJIY) third-quarter fiscal 2020 results are expected to reflect robust performance of the Healthcare business.

  • Fujifilm X-Pro3 Review: A deliberately difficult street-shooter
    Engadget

    Fujifilm X-Pro3 Review: A deliberately difficult street-shooter

    The Fujifilm X-Pro3 is a strange camera. It's built around a rangefinder design, with an offset optical viewfinder that can swap to an EVF, but its LCD screen is hidden against the body of the camera. Despite the rangefinder design, which can't zoom or change framing through the OVF, it can swap lenses. It can shoot video, but with the aforementioned fold-out screen, it's difficult to monitor or frame your shots. This is a camera really build for people nostalgic for Leica rangefinders, and looking for a camera built for one thing: street photography. If that's what you want, you're probably already lusting after the X-Pro3, for everyone else, it's hard not to recommend the more flexible X-T3 over this camera.